Stocks and Investing Stocks and Investing
Mon, August 16, 2021

Matthew Harrison Maintained (SRPT) at Hold with Decreased Target to $90 on, Aug 16th, 2021


Published on 2024-10-27 17:39:42 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Hold with Decreased Target from $93 to $90 on, Aug 16th, 2021.

Matthew has made no other calls on SRPT in the last 4 months.



There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Anupam Rama of "JP Morgan" Upgraded from Sell to Hold and Decreased Target to $87 on, Thursday, August 5th, 2021
  • Judah Frommer of "Credit Suisse" Maintained at Hold with Increased Target to $75 on, Thursday, August 5th, 2021


These are the ratings of the 2 analyists that currently disagree with Matthew


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Decreased Target to $122 on, Thursday, August 5th, 2021
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $110 on, Tuesday, June 15th, 2021

Contributing Sources